Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement
OBJECTIVE Adult growth hormone deficiency (AGHD) is characterized by abnormalities in body composition and a poor perceived quality of life (QoL). Weight‐based high‐dose growth hormone replacement (GHR) results in improvements in body composition and QoL in AGHD. However, a high patient percentage r...
Gespeichert in:
| Veröffentlicht in: | Clinical endocrinology (Oxford) 2001-06, Vol.54 (6), p.709-717 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 717 |
|---|---|
| container_issue | 6 |
| container_start_page | 709 |
| container_title | Clinical endocrinology (Oxford) |
| container_volume | 54 |
| creator | Ahmad, Aftab M. Hopkins, Marion T. Thomas, Joegi Ibrahim, Hisham Fraser, William D. Vora, Jiten P. |
| description | OBJECTIVE Adult growth hormone deficiency (AGHD) is characterized by abnormalities in body composition and a poor perceived quality of life (QoL). Weight‐based high‐dose growth hormone replacement (GHR) results in improvements in body composition and QoL in AGHD. However, a high patient percentage reported side‐effects on high‐dose GHR resulting in a high rate of patient withdrawal from growth hormone (GH) treatment. High‐dose GH therapy also leads to supraphysiological serum insulin‐like growth factor‐I (IGF‐I) concentrations that have been associated with breast and prostate cancer, raising major concerns over the use of such high‐dose GH regimen in AGHD. The aim of this study was to assess the effects of low‐dose growth hormone replacement (GHR) on body composition and QoL as early as 1 and 3 months.
STUDY DESIGN A prospective, open treatment design study to determine the early effects of low‐dose GH administration on body composition and QoL. GH was initiated at a daily dose of 0·4–0·5 IU, and titrated up to achieve and maintain IGF‐I standard deviation score (IGF‐I SDS) between the median and upper end of the age‐related reference range.
PATIENTS Forty‐six, post‐pituitary surgery, severe AGHD patients (22 women), defined as peak GH response |
| doi_str_mv | 10.1046/j.1365-2265.2001.01275.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70948848</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75870222</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5095-3c622beba4aa0ba94687b599dd7588bff091536aa0803fa436ce4debb45796f83</originalsourceid><addsrcrecordid>eNqNkcFu1DAQhiMEokvhFZCFELcEO44dR4hDWZVdRCkHChwtxxlTL0m8tRPt5tB3r8OuCuqJ01ie758Z6UsSRHBGcMHfbjJCOUvznLMsx5hkmOQly_aPksV943GywBTjFHNenCTPQthgjJnA5dPkhJAiz-OkRXL7wTUT0q7bumAH63qk-gbdjKq1w4ScQa01gGz8bsZ2CGhnh2v0y7tdLNfOd64H1ICx2kKvp3cIjAEduTnpdmnjAjzEPWxbpaGDfniePDGqDfDiWE-T7x_Pr5br9OLr6tPy7CLVDFcspZrneQ21KpTCtaoKLsqaVVXTlEyI2hhcEUZ5bApMjSoo11A0UNcFKytuBD1N3hzmbr27GSEMsrNBQ9uqHtwYZImrQohiBl89ADdu9H28TZJKlJxUlEdIHCDtXQgejNx62yk_SYLl7Edu5KxBzhrk7Ef-8SP3MfryOH-sO2j-Bo9CIvD6CKigVWu86rUN_yxguShZxN4fsJ1tYfrv_XJ5fjm_Yj495G0YYH-fV_635CWN6M_LlVz_WH9bXX0h8jO9A_ECvAE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198761936</pqid></control><display><type>article</type><title>Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ahmad, Aftab M. ; Hopkins, Marion T. ; Thomas, Joegi ; Ibrahim, Hisham ; Fraser, William D. ; Vora, Jiten P.</creator><creatorcontrib>Ahmad, Aftab M. ; Hopkins, Marion T. ; Thomas, Joegi ; Ibrahim, Hisham ; Fraser, William D. ; Vora, Jiten P.</creatorcontrib><description><![CDATA[OBJECTIVE Adult growth hormone deficiency (AGHD) is characterized by abnormalities in body composition and a poor perceived quality of life (QoL). Weight‐based high‐dose growth hormone replacement (GHR) results in improvements in body composition and QoL in AGHD. However, a high patient percentage reported side‐effects on high‐dose GHR resulting in a high rate of patient withdrawal from growth hormone (GH) treatment. High‐dose GH therapy also leads to supraphysiological serum insulin‐like growth factor‐I (IGF‐I) concentrations that have been associated with breast and prostate cancer, raising major concerns over the use of such high‐dose GH regimen in AGHD. The aim of this study was to assess the effects of low‐dose growth hormone replacement (GHR) on body composition and QoL as early as 1 and 3 months.
STUDY DESIGN A prospective, open treatment design study to determine the early effects of low‐dose GH administration on body composition and QoL. GH was initiated at a daily dose of 0·4–0·5 IU, and titrated up to achieve and maintain IGF‐I standard deviation score (IGF‐I SDS) between the median and upper end of the age‐related reference range.
PATIENTS Forty‐six, post‐pituitary surgery, severe AGHD patients (22 women), defined as peak GH response < 9 mU/l to provocative testing. The mean age was 50·4 years (range 26–72). Forty‐three patients required additional pituitary replacement hormones following pituitary surgery and were on optimal doses at recruitment.
MEASUREMENTS Body composition and QoL were assessed prior to GHR and subsequently at 1 and 3 months after initiating GHR. Body mass index (BMI) and waist hip ratio (WHR) were calculated from measurements of height, weight, and waist and hip circumference, respectively. Bioelectrical impedance analysis (BIA) was used to determine body fat and lean body mass. QoL was assessed using the disease‐specific ‘QoL‐assessment of growth hormone deficiency in adults (QoL‐AGHDA)’ questionnaire. Serum IGF‐I was measured at each visit to assess the adequacy of GHR.
RESULTS IGF‐I and IGF‐I SDS increased significantly at 1 and 3 months (P < 0·001) after commencing GHR. The increase in IGF‐I (P < 0·05) and IGF‐I SDS (P < 0·01) was significant between 1 and 3 months in the absence of any significant increase in GH dose (P = ns) during this period. Eighty‐five per cent of patients achieved IGF‐I SDS levels between median and upper end of the age‐related reference range after 3 months of GHR, and no side‐effects were reported during this period. There was a significant reduction in body fat percentage (BFP) from 36·1 ± 9·1% at baseline to 34·9 ± 9·3% (P < 0·01) at 1 month and 34·1 ± 9·2% (P < 0·001) at 3 months. Body fat mass (BFM) reduced from 32·8 ± 13·6 kg at baseline to 31·9 ± 13·9 kg at 1 month (P < 0·05) and 31·1 ± 13·6 kg at 3 months (P < 0·001). These changes in BFP and BFM occurred in the absence of any significant change in BMI and WHR (P = ns). Lean body mass (LBM) was 55·9 ± 11·1 kg at baseline and increased to 57·1 ± 11·3 kg after 1 month (P < 0·01) and to 57·6 ± 11·5 kg (P < 0·001) after 3 months of GHR. Significant improvement was observed in the perceived QoL with the AGHD assessment scores reducing from 13·3 ± 6·4 to 11·5 ± 6·6 within 1 month (P < 0·01) and 10·0 ± 6·6 at 3 months (P < 0·001). There was no significant correlation between improvement in QoL and changes in body fat percentage (r = 0·01 at 1 month and r = 0·12 at 3 months, P = ns) or IGF‐I levels (r = 0·04 and r = 0·003, P = ns at 1 and 3 months, respectively). The improvement in body composition and QoL was significant between 1 and 3 months.
CONCLUSIONS Low‐dose GHR improves body composition and QoL as early as 1 month after commencement and the beneficial effects continue at 3 months. Most importantly, these changes occur in the absence of side‐effects. We therefore suggest the use of low‐dose GH therapy, maintaining IGF‐I between the median and upper end of the age‐related reference range, for the treatment of AGHD.]]></description><identifier>ISSN: 0300-0664</identifier><identifier>EISSN: 1365-2265</identifier><identifier>DOI: 10.1046/j.1365-2265.2001.01275.x</identifier><identifier>PMID: 11422104</identifier><identifier>CODEN: CLECAP</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Analysis of Variance ; Biological and medical sciences ; Body Composition - drug effects ; Drug Administration Schedule ; Female ; Growth Disorders - blood ; Growth Disorders - drug therapy ; Growth Disorders - psychology ; Growth Hormone - administration & dosage ; Growth Hormone - blood ; Growth Hormone - deficiency ; Hormones. Endocrine system ; Human Growth Hormone - administration & dosage ; Humans ; Insulin-Like Growth Factor I - metabolism ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Prospective Studies ; Quality of Life ; Reference Values</subject><ispartof>Clinical endocrinology (Oxford), 2001-06, Vol.54 (6), p.709-717</ispartof><rights>2001 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Jun 2001</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5095-3c622beba4aa0ba94687b599dd7588bff091536aa0803fa436ce4debb45796f83</citedby><cites>FETCH-LOGICAL-c5095-3c622beba4aa0ba94687b599dd7588bff091536aa0803fa436ce4debb45796f83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2265.2001.01275.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2265.2001.01275.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1052875$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11422104$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ahmad, Aftab M.</creatorcontrib><creatorcontrib>Hopkins, Marion T.</creatorcontrib><creatorcontrib>Thomas, Joegi</creatorcontrib><creatorcontrib>Ibrahim, Hisham</creatorcontrib><creatorcontrib>Fraser, William D.</creatorcontrib><creatorcontrib>Vora, Jiten P.</creatorcontrib><title>Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement</title><title>Clinical endocrinology (Oxford)</title><addtitle>Clin Endocrinol (Oxf)</addtitle><description><![CDATA[OBJECTIVE Adult growth hormone deficiency (AGHD) is characterized by abnormalities in body composition and a poor perceived quality of life (QoL). Weight‐based high‐dose growth hormone replacement (GHR) results in improvements in body composition and QoL in AGHD. However, a high patient percentage reported side‐effects on high‐dose GHR resulting in a high rate of patient withdrawal from growth hormone (GH) treatment. High‐dose GH therapy also leads to supraphysiological serum insulin‐like growth factor‐I (IGF‐I) concentrations that have been associated with breast and prostate cancer, raising major concerns over the use of such high‐dose GH regimen in AGHD. The aim of this study was to assess the effects of low‐dose growth hormone replacement (GHR) on body composition and QoL as early as 1 and 3 months.
STUDY DESIGN A prospective, open treatment design study to determine the early effects of low‐dose GH administration on body composition and QoL. GH was initiated at a daily dose of 0·4–0·5 IU, and titrated up to achieve and maintain IGF‐I standard deviation score (IGF‐I SDS) between the median and upper end of the age‐related reference range.
PATIENTS Forty‐six, post‐pituitary surgery, severe AGHD patients (22 women), defined as peak GH response < 9 mU/l to provocative testing. The mean age was 50·4 years (range 26–72). Forty‐three patients required additional pituitary replacement hormones following pituitary surgery and were on optimal doses at recruitment.
MEASUREMENTS Body composition and QoL were assessed prior to GHR and subsequently at 1 and 3 months after initiating GHR. Body mass index (BMI) and waist hip ratio (WHR) were calculated from measurements of height, weight, and waist and hip circumference, respectively. Bioelectrical impedance analysis (BIA) was used to determine body fat and lean body mass. QoL was assessed using the disease‐specific ‘QoL‐assessment of growth hormone deficiency in adults (QoL‐AGHDA)’ questionnaire. Serum IGF‐I was measured at each visit to assess the adequacy of GHR.
RESULTS IGF‐I and IGF‐I SDS increased significantly at 1 and 3 months (P < 0·001) after commencing GHR. The increase in IGF‐I (P < 0·05) and IGF‐I SDS (P < 0·01) was significant between 1 and 3 months in the absence of any significant increase in GH dose (P = ns) during this period. Eighty‐five per cent of patients achieved IGF‐I SDS levels between median and upper end of the age‐related reference range after 3 months of GHR, and no side‐effects were reported during this period. There was a significant reduction in body fat percentage (BFP) from 36·1 ± 9·1% at baseline to 34·9 ± 9·3% (P < 0·01) at 1 month and 34·1 ± 9·2% (P < 0·001) at 3 months. Body fat mass (BFM) reduced from 32·8 ± 13·6 kg at baseline to 31·9 ± 13·9 kg at 1 month (P < 0·05) and 31·1 ± 13·6 kg at 3 months (P < 0·001). These changes in BFP and BFM occurred in the absence of any significant change in BMI and WHR (P = ns). Lean body mass (LBM) was 55·9 ± 11·1 kg at baseline and increased to 57·1 ± 11·3 kg after 1 month (P < 0·01) and to 57·6 ± 11·5 kg (P < 0·001) after 3 months of GHR. Significant improvement was observed in the perceived QoL with the AGHD assessment scores reducing from 13·3 ± 6·4 to 11·5 ± 6·6 within 1 month (P < 0·01) and 10·0 ± 6·6 at 3 months (P < 0·001). There was no significant correlation between improvement in QoL and changes in body fat percentage (r = 0·01 at 1 month and r = 0·12 at 3 months, P = ns) or IGF‐I levels (r = 0·04 and r = 0·003, P = ns at 1 and 3 months, respectively). The improvement in body composition and QoL was significant between 1 and 3 months.
CONCLUSIONS Low‐dose GHR improves body composition and QoL as early as 1 month after commencement and the beneficial effects continue at 3 months. Most importantly, these changes occur in the absence of side‐effects. We therefore suggest the use of low‐dose GH therapy, maintaining IGF‐I between the median and upper end of the age‐related reference range, for the treatment of AGHD.]]></description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis of Variance</subject><subject>Biological and medical sciences</subject><subject>Body Composition - drug effects</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Growth Disorders - blood</subject><subject>Growth Disorders - drug therapy</subject><subject>Growth Disorders - psychology</subject><subject>Growth Hormone - administration & dosage</subject><subject>Growth Hormone - blood</subject><subject>Growth Hormone - deficiency</subject><subject>Hormones. Endocrine system</subject><subject>Human Growth Hormone - administration & dosage</subject><subject>Humans</subject><subject>Insulin-Like Growth Factor I - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Quality of Life</subject><subject>Reference Values</subject><issn>0300-0664</issn><issn>1365-2265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkcFu1DAQhiMEokvhFZCFELcEO44dR4hDWZVdRCkHChwtxxlTL0m8tRPt5tB3r8OuCuqJ01ie758Z6UsSRHBGcMHfbjJCOUvznLMsx5hkmOQly_aPksV943GywBTjFHNenCTPQthgjJnA5dPkhJAiz-OkRXL7wTUT0q7bumAH63qk-gbdjKq1w4ScQa01gGz8bsZ2CGhnh2v0y7tdLNfOd64H1ICx2kKvp3cIjAEduTnpdmnjAjzEPWxbpaGDfniePDGqDfDiWE-T7x_Pr5br9OLr6tPy7CLVDFcspZrneQ21KpTCtaoKLsqaVVXTlEyI2hhcEUZ5bApMjSoo11A0UNcFKytuBD1N3hzmbr27GSEMsrNBQ9uqHtwYZImrQohiBl89ADdu9H28TZJKlJxUlEdIHCDtXQgejNx62yk_SYLl7Edu5KxBzhrk7Ef-8SP3MfryOH-sO2j-Bo9CIvD6CKigVWu86rUN_yxguShZxN4fsJ1tYfrv_XJ5fjm_Yj495G0YYH-fV_635CWN6M_LlVz_WH9bXX0h8jO9A_ECvAE</recordid><startdate>200106</startdate><enddate>200106</enddate><creator>Ahmad, Aftab M.</creator><creator>Hopkins, Marion T.</creator><creator>Thomas, Joegi</creator><creator>Ibrahim, Hisham</creator><creator>Fraser, William D.</creator><creator>Vora, Jiten P.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>200106</creationdate><title>Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement</title><author>Ahmad, Aftab M. ; Hopkins, Marion T. ; Thomas, Joegi ; Ibrahim, Hisham ; Fraser, William D. ; Vora, Jiten P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5095-3c622beba4aa0ba94687b599dd7588bff091536aa0803fa436ce4debb45796f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis of Variance</topic><topic>Biological and medical sciences</topic><topic>Body Composition - drug effects</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Growth Disorders - blood</topic><topic>Growth Disorders - drug therapy</topic><topic>Growth Disorders - psychology</topic><topic>Growth Hormone - administration & dosage</topic><topic>Growth Hormone - blood</topic><topic>Growth Hormone - deficiency</topic><topic>Hormones. Endocrine system</topic><topic>Human Growth Hormone - administration & dosage</topic><topic>Humans</topic><topic>Insulin-Like Growth Factor I - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Quality of Life</topic><topic>Reference Values</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ahmad, Aftab M.</creatorcontrib><creatorcontrib>Hopkins, Marion T.</creatorcontrib><creatorcontrib>Thomas, Joegi</creatorcontrib><creatorcontrib>Ibrahim, Hisham</creatorcontrib><creatorcontrib>Fraser, William D.</creatorcontrib><creatorcontrib>Vora, Jiten P.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical endocrinology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ahmad, Aftab M.</au><au>Hopkins, Marion T.</au><au>Thomas, Joegi</au><au>Ibrahim, Hisham</au><au>Fraser, William D.</au><au>Vora, Jiten P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement</atitle><jtitle>Clinical endocrinology (Oxford)</jtitle><addtitle>Clin Endocrinol (Oxf)</addtitle><date>2001-06</date><risdate>2001</risdate><volume>54</volume><issue>6</issue><spage>709</spage><epage>717</epage><pages>709-717</pages><issn>0300-0664</issn><eissn>1365-2265</eissn><coden>CLECAP</coden><abstract><![CDATA[OBJECTIVE Adult growth hormone deficiency (AGHD) is characterized by abnormalities in body composition and a poor perceived quality of life (QoL). Weight‐based high‐dose growth hormone replacement (GHR) results in improvements in body composition and QoL in AGHD. However, a high patient percentage reported side‐effects on high‐dose GHR resulting in a high rate of patient withdrawal from growth hormone (GH) treatment. High‐dose GH therapy also leads to supraphysiological serum insulin‐like growth factor‐I (IGF‐I) concentrations that have been associated with breast and prostate cancer, raising major concerns over the use of such high‐dose GH regimen in AGHD. The aim of this study was to assess the effects of low‐dose growth hormone replacement (GHR) on body composition and QoL as early as 1 and 3 months.
STUDY DESIGN A prospective, open treatment design study to determine the early effects of low‐dose GH administration on body composition and QoL. GH was initiated at a daily dose of 0·4–0·5 IU, and titrated up to achieve and maintain IGF‐I standard deviation score (IGF‐I SDS) between the median and upper end of the age‐related reference range.
PATIENTS Forty‐six, post‐pituitary surgery, severe AGHD patients (22 women), defined as peak GH response < 9 mU/l to provocative testing. The mean age was 50·4 years (range 26–72). Forty‐three patients required additional pituitary replacement hormones following pituitary surgery and were on optimal doses at recruitment.
MEASUREMENTS Body composition and QoL were assessed prior to GHR and subsequently at 1 and 3 months after initiating GHR. Body mass index (BMI) and waist hip ratio (WHR) were calculated from measurements of height, weight, and waist and hip circumference, respectively. Bioelectrical impedance analysis (BIA) was used to determine body fat and lean body mass. QoL was assessed using the disease‐specific ‘QoL‐assessment of growth hormone deficiency in adults (QoL‐AGHDA)’ questionnaire. Serum IGF‐I was measured at each visit to assess the adequacy of GHR.
RESULTS IGF‐I and IGF‐I SDS increased significantly at 1 and 3 months (P < 0·001) after commencing GHR. The increase in IGF‐I (P < 0·05) and IGF‐I SDS (P < 0·01) was significant between 1 and 3 months in the absence of any significant increase in GH dose (P = ns) during this period. Eighty‐five per cent of patients achieved IGF‐I SDS levels between median and upper end of the age‐related reference range after 3 months of GHR, and no side‐effects were reported during this period. There was a significant reduction in body fat percentage (BFP) from 36·1 ± 9·1% at baseline to 34·9 ± 9·3% (P < 0·01) at 1 month and 34·1 ± 9·2% (P < 0·001) at 3 months. Body fat mass (BFM) reduced from 32·8 ± 13·6 kg at baseline to 31·9 ± 13·9 kg at 1 month (P < 0·05) and 31·1 ± 13·6 kg at 3 months (P < 0·001). These changes in BFP and BFM occurred in the absence of any significant change in BMI and WHR (P = ns). Lean body mass (LBM) was 55·9 ± 11·1 kg at baseline and increased to 57·1 ± 11·3 kg after 1 month (P < 0·01) and to 57·6 ± 11·5 kg (P < 0·001) after 3 months of GHR. Significant improvement was observed in the perceived QoL with the AGHD assessment scores reducing from 13·3 ± 6·4 to 11·5 ± 6·6 within 1 month (P < 0·01) and 10·0 ± 6·6 at 3 months (P < 0·001). There was no significant correlation between improvement in QoL and changes in body fat percentage (r = 0·01 at 1 month and r = 0·12 at 3 months, P = ns) or IGF‐I levels (r = 0·04 and r = 0·003, P = ns at 1 and 3 months, respectively). The improvement in body composition and QoL was significant between 1 and 3 months.
CONCLUSIONS Low‐dose GHR improves body composition and QoL as early as 1 month after commencement and the beneficial effects continue at 3 months. Most importantly, these changes occur in the absence of side‐effects. We therefore suggest the use of low‐dose GH therapy, maintaining IGF‐I between the median and upper end of the age‐related reference range, for the treatment of AGHD.]]></abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>11422104</pmid><doi>10.1046/j.1365-2265.2001.01275.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-0664 |
| ispartof | Clinical endocrinology (Oxford), 2001-06, Vol.54 (6), p.709-717 |
| issn | 0300-0664 1365-2265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70948848 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Aged, 80 and over Analysis of Variance Biological and medical sciences Body Composition - drug effects Drug Administration Schedule Female Growth Disorders - blood Growth Disorders - drug therapy Growth Disorders - psychology Growth Hormone - administration & dosage Growth Hormone - blood Growth Hormone - deficiency Hormones. Endocrine system Human Growth Hormone - administration & dosage Humans Insulin-Like Growth Factor I - metabolism Male Medical sciences Middle Aged Pharmacology. Drug treatments Prospective Studies Quality of Life Reference Values |
| title | Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T08%3A16%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Body%20composition%20and%20quality%20of%20life%20in%20adults%20with%20growth%20hormone%20deficiency;%20effects%20of%20low-dose%20growth%20hormone%20replacement&rft.jtitle=Clinical%20endocrinology%20(Oxford)&rft.au=Ahmad,%20Aftab%20M.&rft.date=2001-06&rft.volume=54&rft.issue=6&rft.spage=709&rft.epage=717&rft.pages=709-717&rft.issn=0300-0664&rft.eissn=1365-2265&rft.coden=CLECAP&rft_id=info:doi/10.1046/j.1365-2265.2001.01275.x&rft_dat=%3Cproquest_cross%3E75870222%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198761936&rft_id=info:pmid/11422104&rfr_iscdi=true |